03:13 PM EDT, 05/15/2025 (MT Newswires) -- Incyte ( INCY ) said Thursday that the US Food and Drug Administration has approved Zynyz for the treatment of advanced squamous cell carcinoma of the anal canal in combination with chemotherapy and as a monotherapy.

Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival in SCAC patients, the company said.

Shares of Incyte ( INCY ) were up almost 2% in recent trading.

Price: 62.36, Change: +1.20, Percent Change: +1.96